Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- Japan’s Application for Membership in PIC/S Reported: PIC/S General Meeting
May 11, 2012
- Risk Management Plans Must Be Submitted By 1 Month Prior to Launch: MHLW Notification
May 8, 2012
- Gov’t, Industry Leaders to Meet on May 10 for Second Dialogue on 5-Year Medical Innovation Strategy
May 8, 2012
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
- CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
- IPV Vaccination Set to Begin in September; Adequate Supplies Expected
April 25, 2012
- Drug Discovery Support Network to Be Coordinated by NIBIO: 5-Year Strategy for Medical Innovation
April 25, 2012
- Medicoeconomic Assessment Should Initially Be Used in Reevaluating Existing Drugs: Dr Fukuda of NIPH
April 24, 2012
- HTA Should Be Used for NHI Drug Pricing, Not Reimbursement: Prof. Endo at DPJ Hearings
April 24, 2012
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
- MHLW Aims to Begin IPV Vaccination in September: Health Minister Komiyama
April 23, 2012
- MHLW Issues Improvement Order to Pfizer for GMP Violation at US BVL Plant
April 20, 2012
- PAL Amendment: Proposal Emerges to Submit Legislation by Diet Members for Third Party Organization
April 19, 2012
- Discussions on Use of Cost-Effectiveness Assessments to Begin with Advanced but Costly Technologies: MED Director Suzuki
April 19, 2012
- DPJ Working Team to Hold Hearings on Cost-Effectiveness Assessments, Pricing of Long-Listed Drugs on April 20
April 19, 2012
- Risk Management Plans to Be Required from April 2013 to Strengthen Post-Marketing Safety Measures
April 18, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…